The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: Implications for the development of vaccines and antiviral agents

Viral Immunology

Volumn 27, Issue 10, 2014, Pages 543-550

  Yang, Yang ^a   Deng, Yao ^a   Wen, Bo ^a   Wang, Huijuan ^a   Meng, Xin ^a   Lan, Jiaming ^a   Gao, George F ^b   Tan, Wenjie ^a  

^a BEIJING HOSPITAL   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; KEYHOLE LIMPET HEMOCYANIN; NEUTRALIZING ANTIBODY; PEPTIDE ANTIBODY; RECOMBINANT PROTEIN; SPIKE PROTEIN2 1 PEPTIDE ANTIBODY; SPIKE PROTEIN2 2 PEPTIDE ANTIBODY; SPIKE PROTEIN3 PEPTIDE ANTIBODY; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN; VITRONECTIN; CORONAVIRUS SPIKE GLYCOPROTEIN; EPITOPE; VIRUS ANTIBODY; VIRUS VACCINE;

ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; BHK CELL LINE; CONTROLLED STUDY; CORONAVIRUS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOFLUORESCENCE; IN VITRO STUDY; MASS SPECTROMETRY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVVIRUS; MOUSE; NONHUMAN; PROTEIN DOMAIN; RAT; RECEPTOR BINDING; SARS CORONAVIRUS; VIRUS ATTACHMENT; VIRUS ENTRY; ANIMAL; BAGG ALBINO MOUSE; BIOLOGY; BLOOD; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PHYSIOLOGY; RABBIT; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BLOTTING, WESTERN; COMPUTATIONAL BIOLOGY; EPITOPES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; MICE; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RABBITS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRAL VACCINES; VIRUS INTERNALIZATION;

EID: 84915817585     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2014.0080     Document Type: Article

References (30)

1. Belouzard S, Millet JK, Licitra BN, and Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 2012;4: 1011-1033.
2. Breban R, Riou J, and Fontanet A. Interhuman transmis-sibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet 2013;382:694-699.
3. Coughlin MM, Babcook J, and Prabhakar BS. Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms. Virology 2009;394:39-46.
4. de Groot RJ, Cowley JA, Enjuanes L, et al. Order of ni-dovirales. In: King A, Adams M, Carstens E, and Lefkowitz EJ, eds. Virus Taxonomy. The 9th report of the International Committee on Taxonomy of Viruses. San Diego, Academic Press, 2012:785-795.
5. deGroot RJ, Baker SC, Baric RS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 2013; 87: 7790-7792.
6. Du L, He Y, Zhou Y, Liu S, Zheng BJ, and Jiang S. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol 2009;7:226-236.
7. Du L, Kou Z, Ma C, et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 2013;8:e81587.
8. Du L, Zhao G, Kou Z, et al. Identification of receptor-binding domain in S protein of the novel human cor-onavirus MERS-CoV as an essential target for vaccine development. J Virol 2013;87:9939-9942.
9. Gao J, Lu G, Qi J, et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome cor-onavirus. J Virol 2013;87:13134-13140.
10. Gierer S, Bertram S, Kaup F, et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus re-ceptorforentry, canbeactivatedbyTMPRSS2, andistargeted by neutralizing antibodies. J Virol 2013;87:5502-5511.
11. He Y, Lu H, Siddiqui P, Zhou Y, and Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005;174:4908-4915.
12. Holmes KV, and Dominguez SR. The new age of virus discovery: genomic analysis of a novel human betacor-onavirus isolated from a fatal case of pneumonia. mBio 2013;4:e00548-12.
13. Hotez PJ, Bottazzi ME, Tseng CT, et al. Calling for rapid development of a safe and effective MERS vaccine. Microbes Infect 2014;pii:S1286-4579(14)00065-3.
14. Jiang S, Bottazzi ME, Du L, et al. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines 2012;11:1405-1413.
15. Kuhn JH, Li W, Choe H, and Farzan M. Angiotensin-converting enzyme 2: a functional receptor for the SARS coronavirus. Cell Mol Life Sci 2004;61:2738-2743.
16. Lee A, Powell JE, Tregear GW, Niall HD, and Stevens VC. A method for preparing fl-hCG COOH peptide-carrier conjugates of predictable composition. Mol Immunol 1980;17:749-756.
17. Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013;500:227-231.
18. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, and Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013;368:2487-2494.
19. Miyoshi-Akiyama T, Ishida I, Fukushi M, et al. Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model. J Infect Dis 2011;203:1574-1581.
20. Mou H, Raj VS, van Kuppeveld FJ, Rottier PJ, Haagmans BL, and Bosch BJ. The receptor binding domain of the new MERS coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 2013;87:9379-9383.
21. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013;495:251-254.
22. Raj VS, Osterhaus AD, Fouchier RA, and Haagmans BL. MERS: emergence of a novel human coronavirus. Curr Opin Virol 2014;5:58-62.
23. Snijders A, Benaissa-Trouw BJ, Oosterlaken TA, et al. Identification of linear epitopes on Semliki Forest virus E2 membrane protein and their effectiveness as a synthetic peptide vaccine. J Gen Virol 1991;72 (Pt 3):557-565
24. The Who Mers-Cov Research Group. State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Cor-onavirus (MERS-CoV) in Humans. PLoS Curr 2013;5:pii: ecurrents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8.
25. van Boheemen S, de Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 2012;3:e00473-12.
26. Wang N, Shi X, Jiang L, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013;23:986-993.
27. World Health Organization. Novel coronavirus infection-update. www.who.int/csr/don/2014-07-04-mers/en/, 2014.
28. Yan K, Tan W, Wang H, et al. SARS-CoV spike proteins expressed by the vaccinia virus Tiantan strain: secreted sq protein induces robust neutralization antibody in mice. Viral Immunol 2009;22:57-66.
29. Yang Y, Zhang L, Geng H, et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 2013;4: 951-961.
30. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, and Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-1820.